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a b s t r a c t
KSHV establishes characteristic latent infections in vitro, while RRV, a related macaque rhadinovirus,
establishes characteristic permissive infections with virus replication. We identiﬁed cells that are not
permissive for RRV replication and recapitulate the latent KSHV infection and reactivation processes. The
RRV replication and transactivator (Rta) promoter was characterized in permissive and non-permissive
cells and compared to the KSHV Rta promoter. Both promoters contained a critical Sp1 element, had
equivalent activities in different cell types, and were inhibited by LANA. RRV and KSHV infections were
non-permissive in cells with low Rta promoter activity. While RRV infections were permissive in cells
with high basal promoter activity, KSHV infections remained non-permissive. Our studies suggest that
RRV lacks the Rta-inducible LANA promoter that is responsible for LANA inhibition of the KSHV Rta
promoter and induction of latency during KSHV infection. Instead, the outcome of RRV infection is
determined by host factors, such as Sp1.
& 2013 Elsevier Inc. All rights reserved.
Introduction
The human rhadinovirus Kaposi's sarcoma herpesvirus (KSHV)
has been associated with all forms of Kaposi's sarcoma (KS) and
two AIDS-related lymphoproliferative disorders (Cohen et al.,
2005; Sarid et al., 1999a). In KS tumors in vivo and infected
cultures in vitro the vast majority of cells are latently infected,
with only a small percentage of cells undergoing active replication.
Our understanding of the replicative program of infection is
limited because a natural permissive system has not been identi-
ﬁed for KSHV. In order to achieve high levels of replication in vitro,
latent KSHV is commonly reactivated by treatment with histone
deacetylase (HDAC) inhibitors like sodium butyrate or phorbol
esters such as TPA. KSHV replication can also be induced by
overexpression of the viral replication and transactivator (Rta),
encoded by open reading frame (ORF) 50. Rta is the only viral gene
that is necessary and sufﬁcient for virus replication (Lukac et al.,
1999; Sun et al., 1998). Because of its central role in the reactiva-
tion of KSHV, Rta is considered to be the master regulator of
reactivation and its function has been extensively studied
(Gradoville et al., 2000; Lukac et al., 1998; Sun et al., 1998).
Rta activates viral promoters through both direct DNA binding
and interactions with cellular transcription factors (Lukac et al.,
2001; Sakakibara et al., 2001; Song et al., 2002). Numerous
regulatory elements have been identiﬁed in the Rta promoter,
including binding sites for the cellular transcription factors Oct1, C/
EBP, Sp1, Ap1, XBP-1, and YY1 (Chang et al., 2011; Lu et al., 2003;
Sakakibara et al., 2001; Wang et al., 2003, 2004; Wilson et al.,
2007; Ye et al., 2005; Yu et al., 2007). Furthermore, the KSHV
latency-associated nuclear antigen (LANA) and the virally encoded
microRNAs negatively regulate Rta expression to promote the
establishment and maintenance of latency (Bellare and Ganem,
2009; Lan et al., 2004). Analysis of gene expression in latently
infected cells following butyrate treatment demonstrated that Rta
is one of the ﬁrst genes induced after biochemical reactivation,
with expression occurring within 4 h (Ye et al., 2007). Studies have
found that butyrate directly induces the KSHV Rta promoter, and
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the butyrate-responsive element has been mapped to an Sp1-
binding site 103 to 112 nucleotides upstream of the translational
start site (Lu et al., 2003; Ye et al., 2005).
Two studies of early gene expression kinetics during KSHV
infection have shed light on the events that lead to the establish-
ment of latency in infected cells. Both studies reported a discrete
but transient increase in Rta expression early after infection
(Krishnan et al., 2004; Lan et al., 2005). Early Rta expression is
thought to be regulated by the pre-existing balance of host factors
present in the infected cell, as has been described for the
transactivator genes of other herpesviruses (Gelman and
Silverstein, 1987). Additionally, Rta has been identiﬁed as a
component of the KSHV virion, and the early surge in Rta
expression may, in part, be due to promoter auto-activation by
virion-associated Rta (Bechtel et al., 2005; Harrison and
Whitehouse, 2008). Instead of inducing active viral replication,
however, Rta levels decline rapidly after KSHV infection and LANA
levels steadily increase, peaking at 24 h post-infection. At this time
point LANA protein has readily accumulated in the nuclei of
infected cells and viral latency is established. The steep decline
in Rta levels after KSHV infection is thought to be a result of the
inhibitory effects of LANA as it accumulates in the infected cell
(Lan et al., 2004).
The early spike in Rta levels after infection prompted investiga-
tion into the role of Rta in the establishment of KSHV latency.
A series of recent reports demonstrated that KSHV Rta induces
LANA expression early in infection through an Rta-responsive
promoter (LANApi) and that Rta-mediated activation of LANApi
is critical for the establishment of KSHV latency (Lan et al., 2005;
Lu et al., 2011). LANApi is located in the intron region that is
excised during maturation of the latent transcript and is distinct
from the constitutive promoter (LANApc) that regulates LANA
expression in latently infected cells (Dittmer et al., 1998;
Matsumura et al., 2005; Pearce et al., 2005; Sarid et al., 1999b;
Talbot et al., 1999). KSHV Rta activates LANApi through interaction
with the cellular transcription factor RBP-Jkappa (RBP-Jk), a down-
stream effector of the Notch signaling pathway (Nellesen et al.,
1999). Rta and RBP-Jk form a complex at LANApi, and DNA binding
is mediated by an Rta-responsive element (RRE) and two RBP-Jk
binding sites in the promoter region (Lan et al., 2005). Deletion of
either RBP-Jk binding site abolishes LANApi activity and results in
a diminished ability of the KSHV to establish latency (Hilton and
Dittmer, 2012; Lu et al., 2011). These studies suggest that LANA
and Rta together comprise a regulatory loop early in KSHV
infection that leads to the establishment of viral latency: early
expression of Rta activates the LANApi promoter and induces high-
level expression of LANA. LANA shuts off Rta expression through
transcriptional repression, ultimately resulting in the establish-
ment of latency in the infected cell.
Two distinct lineages of rhadinoviruses have been identiﬁed in Old
World primate species (Greensill et al., 2000b; Schultz et al., 2000).
The RV1 rhadinovirus lineage consists of KSHV and its close evolu-
tionary homologs from different non-human primate species
(Greensill et al., 2000a, 2000b; Lacoste et al., 2000a; Rose et al.,
1997). The RV2 rhadinovirus lineage is evolutionarily distinct from
KSHV and the RV1 homologs. Members of the RV2 lineage have been
detected in the same non-human primate species that are host to the
RV1 rhadinoviruses (Bruce et al., 2005; Desrosiers et al., 1997; Greensill
et al., 2000b; Lacoste et al., 2000b, 2001) and individual animals can
be co-infected with both RV1 and RV2 viruses (Schultz et al., 2000).
Though RV2-lineage viruses have been found in numerous Old World
primate species, an RV2-lineage rhadinovirus has not yet been
identiﬁed in humans. Two variants of the rhesus rhadinovirus (RRV),
the prototypical RV2-lineage virus, have been identiﬁed and full
genome sequencing identiﬁed few strain differences. A comparison
with the genome of KSHV showed that the RRV was highly homo-
logous and co-linear with KSHV, although several differences were
noted (Desrosiers et al., 1997; Searles et al., 1999). Major differences
include the lack of the K3 and K5 immune evasion genes that are
believed to be important for maintaining KSHV latency and the
expansion of the viral interferon regulator factor (IRF) genes that
control the host immune response to RRV infection (Alexander et al.,
2000; Robinson et al., 2012).
In vitro, tissue culture cells are permissive for RRV replication
and produce high titers of infectious virus (Desrosiers et al., 1997;
DeWire et al., 2003). In vivo, RRV is associated with a distinct
group of T-cell and B-cell lymphomas in macaques that express
markers of viral replication and contain high levels of RRV DNA
(Bruce et al., 2012). Because of this replicative phenotype, RRV
represents a useful system to study the determinants of rhadino-
virus replication. RRV encodes an Rta homolog that has consider-
able homology to KSHV Rta across functional domains including
the DNA binding region (Lin et al., 2002). Studies have conﬁrmed
that RRV Rta is expressed early in infection (Bruce et al., 2009;
Damania et al., 2004; Dittmer et al., 2005; Lin et al., 2002) and
functions as a potent transactivator of viral promoters (Damania
et al., 2004; Dittmer et al., 2005; Lin et al., 2002). While ectopic
expression of RRV LANA has been shown to decrease virus
replication in permissive cells, no direct inhibitory effects of LANA
on the RRV Rta promoter have been detected (DeWire and
Damania, 2005). The reasons that RRV and KSHV establish differ-
ent programs of infection are not completely understood.
We have previously characterized RRV replication in rhesus
primary fetal ﬁbroblast (RPFF) and Vero cells using RV2-speciﬁc
assays, and have shown that both cell lines are permissive for RRV
infection, with lytic gene expression and production of infectious
virus (Bruce et al., 2009). Here, we have identiﬁed a novel natural
infection system to study RRV latency in two orogastric epithelial
cell lines that are non-permissive for RRV replication. We demon-
strate that the RRV Rta promoter is highly active in cells that are
permissive for virus replication, but only minimally active in non-
permissive cells, in which RRV infection is latent. As in KSHV, an
Table 1
Permissivity of cell lines to RRV infection.
Cell line RPFF Vero HEK293 HSG HSGþNaButd AGS AGSþNaBut
ORF59 “early gene” expressiona þe,g þe,g þg g þg -g þg
Local virus transmissionb þe,g þe,g þg g þg -g þg
Production of infectious virionsc þe,f þe,g þg g þg ndh nd
a Positive nuclear immunoﬂuorescence detected with rabbit anti-RV2 ORF59 antiserum.
b Expanding foci of ORF59-positive cells post infection.
c Infectious RRV virions in supernatent of post infection, titered on permissive RPFF cells.
d NaBut¼sodium butyrate treated.
e Bruce et al., 2009.
f DesRosiers et al., 1997; Searles et al., 1999; DeWire et al., 2003.
g This study.
h nd¼not determined.
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Sp1 response element was identiﬁed in the RRV Rta promoter that
was critical for high-level Rta promoter activity. We further show
that ectopic expression of RRV LANA inhibited Rta promoter
activity and viral replication, as has been shown for KSHV LANA.
However, RRV lacks a conserved homolog of the LANApi promoter
required for the establishment of latency in KSHV, suggesting that
the differential permissivity observed in RRV and KSHV infections
may be due to differences in the induction and expression of
LANA, rather than differences in Rta function. Our study demon-
strates that RRV Rta promoter activity strongly correlates with
cellular permissivity for viral replication and suggests an impor-
tant role for host cell factors, such as Sp1, in determining whether
RRV infection results in latency or virus replication.
Results
Characterization of cell culture systems permissive and non-
permissive for RRV replication
We and others have previously reported that rhesus ﬁbroblasts
and Vero kidney epithelial cells are permissive for RRV replication
(Bruce et al., 2009; Desrosiers et al., 1997; DeWire et al., 2003;
Searles et al., 1999) (Table 1). We have shown that RRV-infected
rhesus primary fetal ﬁbroblast (RPFF) and Vero cultures contain
large numbers of cells expressing the ORF59 DNA polymerase
processivity factor, an early marker of the lytic cycle, and produce
high titers of infectious virus (Bruce et al., 2009). In these
permissive cell lines, ORF59 mRNA was expressed early after
RRV infection and ORF59 protein accumulated in the nuclei of
infected cells. Expression and nuclear accumulation of ORF59
increased over time, which strongly correlated with the produc-
tion of infectious virions (Bruce et al., 2009). Furthermore,
expanding foci of ORF59-positive cells were detected, providing
evidence of local transmission in the spreading infection in
permissive cell cultures during the 3-day study.
To identify natural infection systems to study RRV latency,
we screened several cell lines for a non-permissive phenotype.
Because a previous study reported that the human embryonic
kidney cell line (HEK293) was not permissive for RRV replication,
as measured by plaque assay (DeWire and Damania, 2005), we
incubated HEK293 cells with puriﬁed virions and evaluated for the
induction of the lytic gene cascade examining the expression of
RRV ORF59 3 days post-infection using the 425 anti-RV2 ORF59
antibody that reacts with RRV ORF59 (see Materials and methods).
RPFF and Vero cultures were also infected in parallel as positive
controls for viral replication. As seen previously, the RRV-infected
RPFF and Vero cell cultures contained expanding foci of ORF59-
positive cells (Fig. 1A and B), showing activation of the lytic gene
cascade, production of infectious virions and local virus transmis-
sion to adjacent cells (Table 1). Unexpectedly, similar ORF59-
positive foci were also detected in the RRV-infected HEK293 cell
cultures (Fig. 1C). By 3 days, the RRV infection in the HEK293
culture had spread from an initial focus of infection to adjacent
cells, as seen previously with permissive RPFF and Vero cells
(Bruce et al., 2009). To test for the presence of newly replicated
infectious RRV virions, supernatant from the RRV-infected HEK293
cultures was removed and used to infect naïve RPFF cells. Super-
natant from the RRV-infected RPFF cultures was used as a positive
infection control. Three days post-infection similar high levels of
ORF59-positive RRV-infected foci were detected in the naïve RPFF
cell cultures that had been treated with supernatants from either
the RRV-infected HEK293 or RPFF cell cultures (Fig. 2A and B).
These results demonstrated that like RPFF and Vero cells, the
HEK293 cells are permissive for RRV infection with expression of
the ORF59 lytic gene cascade marker and production of infectious
virions (Table 1).
The permissivity of two additional epithelial cell lines, human
salivary gland (HSG) and human gastric adenocarcinoma (AGS),
was evaluated using ORF59 expression as a marker of RRV
replication. The HSG epithelial cell line was originally isolated
from an irradiated submandibular salivary gland and grows as an
undifferentiated monolayer with cuboidal morphology under
normal culture conditions (Shirasuna et al., 1981). The AGS cell
line was established from a surgically resected adenocarcinoma of
the stomach and shown to be epithelial with expression of
cytoplasmic mucin (Barranco et al., 1983). HSG and AGS cell
cultures were incubated with RRV for 3 h and assayed for ORF59
expression 3 days post-infection (pi). Vero cells were infected in
parallel as positive controls. While numerous ORF59-positive cells
were detected in the permissive Vero cell culture 3 days pi, no
ORF59 expression was detected in either the HSG or AGS cell
cultures (Figs. 3A and C). Even though the infected cells did not
Fig. 1. RRV infection induces lytic gene expression in a variety of cell lines from
human and nonhuman Old World primate species. (A) Rhesus primary fetal
ﬁbroblast (RPFF), (B) African green monkey kidney epithelial (Vero), and
(C) human embryonic kidney epithelial (HEK293) cells were infected with RRV
and evaluated three days post-infection for expression of the early lytic gene
marker, the ORF59 DNA polymerase processivity factor, using rabbit anti-RV2
ORF59 antiserum (green), as described in Materials and methods. The merged
image of the ORF59 and Topro-3 (blue) nuclear staining is shown. Images were
acquired by confocal microscopy and are shown as projections of the z-stack. The
magniﬁcation scales are shown. Abundant RRV-infected ORF59-positive cell foci
were detected in all three cell lines.
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express ORF59, which is critical for virus replication, the culture
medium from the infected HSG cells was assayed for the presence
of infectious virions by incubating with permissive RPFF cells, as
described above. As expected, the lack of ORF59 staining corre-
lated with the absence of infectious virions, supporting the ﬁnding
that HSG and AGS cells were not permissive for RRV replication
(Table 1).
By deﬁnition, herpesvirus latency is a reversible state, and the
ability to reactivate replication is considered a hallmark of latent
infection (Speck and Ganem, 2010). Because it is essential for viral
replication, ORF59 expression and nuclear accumulation are com-
monly used as markers of reactivation of KSHV latency (Katano
et al., 1999). Though little is known about latency in RRV, our
ORF59 assay allowed us to evaluate whether viral replication could
be reactivated in RRV-infected HSG and AGS cells. To determine if
RRV had established a non-permissive but latent infection in HSG
and AGS cells we evaluated ORF59 expression in RRV-infected
cultures following treatment with sodium butyrate, an inhibitor of
HDAC activity commonly used to reactivate latent herpesvirus
infections. HSG and AGS cells were infected with RRV for 3 h,
extensively washed to remove free virus, and treated with sodium
butyrate. Three days post-infection, the cells were assayed for
ORF59 expression to detect reactivation of latent RRV infections.
Fig. 2. ORF59 positive RRV-infected cell cultures are permissive for virus replica-
tion and production of infectious virions. Culture supernatant was removed from
ORF59-positive RRV-infected RPFF (A), HEK293 (B) (see Fig. 1) and incubated with
permissive RPFF cells to determine the presence of infectious virus. Similarly,
supernatant from sodium butyrate-treated RRV-infected HSG cell cultures (see
Fig. 3) was incubated with permissive Vero cells. The supernatant-treated cell
cultures were screened for de novo infections using the anti-RV2 ORF59 antiserum
(green) as described above. Similar titers of infectious RRV were detected in the
supernatants of RRV-infected RPFF and HEK293 cell cultures and in the sodium-
butyrate activated RRV-infected HSG cell cultures.
Fig. 3. RRV latently infects orogastric epithelial cells, and activation of lytic gene
expression and virus replication is induced by sodium butyrate. Human salivary
gland (HSG) and gastric adenocarcinoma (AGS) orogastric epithelial cell lines were
incubated with RRV for 3 h and then assayed 3 days post-infection for expression of
RRV ORF59, the DNA polymerase processivity factor, using the 425 rabbit polyclonal
anti-RV2 ORF59 antibody (green) to detect permissive RRV infections (A and C).
Alternatively, HSG and AGS cells were incubated with RRV for 3 h and then cultured
for 3 days in the presence of sodium butyrate (NaBut) to activate latent RRV
infections before evaluation of ORF59 expression (B, D). AGS cells are shown at
lower magniﬁcation to visualize the presence of ORF59-positive nuclei throughout
the culture, in addition to a higher magniﬁcation (shown in panel D, insert). RRV
lytic gene expression was detected in both cell lines after NaBut treatment
indicating that the initial RRV infection was latent and that NaBut activated the
RRV lytic cycle. The magniﬁcation scale bars are shown.
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Numerous ORF59-positive nuclei were detected in RRV-infected
HSG and AGS cell cultures following butyrate treatment (Fig. 3B
and D), in contrast to the untreated cultures. Individual ORF59-
positive nuclei were seen in butyrate-treated AGS cultures, shown
at both low magniﬁcation (Fig. 3D) and high magniﬁcation
(Fig. 3D, insert). In the butyrate-treated HSG cell cultures we
detected foci of infection, which typically showed one cell strongly
staining for ORF59 surrounded by several other cells showing
weaker ORF59 staining (Fig. 3B). The presence of ORF59-positive
foci suggests that the infection had spread during the 3-day
incubation from an initial infected cell to adjacent cells, which
mirrors the spread of RRV infection in permissive RPFF and Vero
cell cultures that we have previously described (Bruce et al., 2009).
To determine whether butyrate treatment resulted in the release
of RRV virions, supernatant from the butyrate-induced HSG cells
was incubated with naive Vero cell cultures. ORF59-positive Vero
cells were detected 2 days post-infection (Fig. 2C), indicating that
butyrate treatment of the HSG cells had induced the production of
infectious RRV virions (Table 1). The ﬁnding that sodium butyrate
induced de novo ORF59 expression in RRV-infected AGS and HSG
cells recapitulates the induction of ORF59 expression after buty-
rate reactivation of latent KSHV infections (Supplementary Fig. S1).
For both KSHV and RRV, butyrate-induced ORF59 expression
correlates with replication and production of infectious virions,
substantiating the similarities in reactivation of latency between
these viruses.
The RRV Rta promoter is highly active in permissive cell lines
The availability of cell lines permissive for RRV replication
allowed us to characterize the RRV Rta promoter in a natural
cellular background that supports the complete lytic cascade,
which has been difﬁcult for KSHV. HEK293 and Vero cells were
transfected with either the pGL2 R-Rta construct, containing 502
nucleotides of RRV Rta promoter sequence upstream of the ﬁreﬂy
luciferase gene, or empty pGL2 vector and luciferase activity
was measured at 24 h. The pRL-CMV construct, in which the
CMV immediate-early (IE) promoter drives expression of Renilla
luciferase, was co-transfected and pGL2 ﬁreﬂy luciferase activity
was normalized to pRL Renilla luciferase activity. The pGL2 R-Rta
construct gave high levels of luciferase activity in both HEK293
and Vero cells (48 RLU) with a 45- and 19-fold increase in activity
over empty pGL2 vector, respectively (Fig. 4). These results
demonstrated that the RRV Rta promoter was highly active in
these permissive cell lines.
The activity of the RRV Rta promoter is low in non-permissive cell
lines, but is highly induced by sodium butyrate treatment
We next examined the activity of the RRV Rta promoter in AGS
and HSG cells, which are non-permissive for RRV replication. Since
butyrate treatment rendered AGS and HSG cells permissive for
RRV replication, we also examined the effects of butyrate treatment
on Rta promoter activity. AGS and HGS cells were transfected with
pGL2 R-Rta and pRL-CMV in triplicate. In half of the cultures, sodium
butyrate was added 5 h post transfection, and luciferase activity was
measured at 24 h. Minimal luciferase activities of 0.66 and 0.81 RLU
were detected in the non-permissive AGS and HSG cells, respectively
(Fig. 5). The transfection control, pRL-CMV, had comparable activity
across all three cell lines (data not shown), indicating that the low
activity of pGL2 R-Rta in AGS and HSG cells was not due to broad
defects in promoter function in these cell lines. The butyrate-treated
AGS and HSG cells had Rta promoter activities of 2.7 and 3.2 RLU
(Fig. 5). The Rta promoter activities in the butyrate-treated cells were
signiﬁcantly higher than the untreated cells, with 3.3 (p¼0.0208) and
4.8 (p¼0.0018) fold increased activity, respectively.
The RRV and KSHV Rta promoters are similar in structure and share a
conserved Sp1 element
In order to identify regulatory elements in the RRV Rta
promoter, the nucleotide sequence of the promoter region directly
upstream of the RRV Rta translational start site was aligned with
the corresponding region of the KSHV Rta promoter. Although the
two promoter regions did not show a high level of sequence
homology, an optimal alignment was obtained that showed a close
relationship between the translational and transcriptional start
sites that have been identiﬁed for KSHV and RRV Rta (DeWire
et al., 2002; Lukac et al., 1999). This alignment contained scattered
regions of conservation extending to the upstream ORF48 transla-
tional start site and coding sequence (Fig. 6A). A conserved TATA-
like promoter motif (TTAAAA) that has been described upstream
of the KSHV Rta transcriptional start site at nucleotides (nt) 67
to 62 (Ye et al., 2005) was conserved in the RRV Rta promoter
region (nt 66 to 61). Similarly, another TATA-like motif
(TATTTA, coding strand) was identiﬁed upstream of the ORF48
start site in both the KSHV and RRV sequences (nt 139 to 144).
Fig. 4. The RRV Rta promoter is highly active in cells that are permissive for RRV
replication. HEK293 and Vero cells were transfected with either the pGL2 R-Rta
promoter construct, containing 502 nucleotides of RRV Rta promoter sequence
driving luciferase expression, or empty pGL2 vector, and assayed for luciferase
activity 24 h post-transfection. Luciferase activity was normalized to the activity of
pRL-CMV, containing the CMV IE promoter driving Renilla expression, which was
co-transfected to control for transfection efﬁciency. Error bars represent the
standard deviation from triplicate wells.
Fig. 5. RRV Rta promoter activity is low in non-permissive cells and is activated by
butyrate treatment. Non-permissive AGS and HSG cells were transfected with the
RRV Rta promoter construct, pGL2 R-Rta. Five hours post-transfection, butyrate was
added to half of the cell cultures and luciferase activity was evaluated at 24 h.
Luciferase activity was normalized to the activity of pRL-CMV, as described in Fig. 4.
Error bars represent the standard deviation from triplicate wells. P values were
calculated using the unpaired t test, two tailed.
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A number of binding sites for cellular transcription factors previously
identiﬁed in the KSHV Rta promoter were mapped on the KSHV
sequence, including a GC box containing nine consecutive guanines
and cytosines (50 GCCCCGCCC 30; nt 112 to 103) that has been
shown to be a binding site for the Sp1 transcription factor in the
KSHV Rta promoter (Lu et al., 2003; Ye et al., 2005). Similar proximal
Sp1-binding sites have been identiﬁed in a wide variety of eukaryotic
promoters (Lania et al., 1997; Nagaoka et al., 2001). The transcription
factor binding prediction program PROMO (Messeguer et al., 2002)
identiﬁed a positionally conserved Sp1 site in the RRV Rta promoter
(GCCACGCCC; nt 113 to 103). Eight of nine nucleotides in the GC
box were identical between the KSHV and RRV Rta promoter
sequences (Fig. 6A). The binding sites for other transcription factors
identiﬁed in the KSHV Rta promoter, including Oct1, Ap1, XBP-1, and
C/EBP, were not well conserved in the RRV Rta promoter.
The conserved Sp1 site in the RRV Rta promoter confers high-level
activity in permissive cells and butyrate responsiveness in non-
permissive cells
To identify speciﬁc regulatory elements in the RRV Rta promo-
ter, we prepared 5' truncations of the promoter region beginning
502 nucleotides upstream of the Rta translational start site. Serial
truncations were cloned into the pGL2 ﬁreﬂy luciferase backbone,
and the activity of each truncation construct was evaluated in Vero
cells, which are permissive for RRV infection. Deletion of nucleo-
tides 502 to 136 did not signiﬁcantly impact promoter activity
(Fig. 6B). This region contains the upstream sequences encoding
ORF48 and its putative TATA-like element. However, further
deletion of nucleotides from 136 to 102 resulted in a dramatic
decrease in promoter activity (Fig. 6C). Similar results were
obtained in HEK293 cells, which are also permissive for RRV
infection (data not shown).
The truncation analysis suggested the presence of a critical
regulatory element between nucleotides 136 and 102. Because
this region contained the Sp1 element conserved between KSHV
and RRV (Fig. 7A), we tested whether the Sp1 site at 113 was
required for RRV Rta promoter activity. The Sp1 element was
eliminated in the full-length pGL2 R-Rta by site-directed mutagen-
esis (Fig. 7A). The activity of the wild type and Sp1 mutant were
analyzed in permissive Vero and HEK293 cells, which have high
basal levels of Rta promoter activity, and in HSG cells that were
treated with sodium butyrate to induce high-level Rta promoter
activity. In HEK293 and Vero cells, the Sp1 mutation abolished RRV
Fig. 6. Deletion analysis of the RRV Rta promoter reveals a critical regulatory region. (A) Comparison of the promoter regions of K-Rta and R-Rta, the replication and transactivator
genes for KSHV and RRV, respectively. Nucleotides 71170–71697 of KSHV (NC_009333.1) and 66858–67364 of RRV (NC_003401.1) genomic sequence were aligned. Nucleotide
numbering indicates the position relative to the Rta translational start site. Identical nucleotides are highlighted in gray. Known transcription factor binding sites for C/EBP, Oct1, YY1,
Ap1, Sp1, and XBP-1 in the KSHV Rta promoter (Chang et al., 2011; Lu et al., 2003; Sakakibara et al., 2001;Wang et al., 2004;Wang et al., 2003; Wilson et al., 2007; Ye et al., 2005; Yu
et al., 2007) are indicated. Of these sites, only the Sp1 binding site was conserved in the RRV Rta promoter. Transcriptional start sites for KSHV Rta and RRV Rta (DeWire et al., 2002;
Lukac et al., 1999) are identiﬁed by solid arrows. Translational start sites for Rta and ORF48 are shownwith block arrows with initiation codons shown in black. TATA-like elements
upstream of ORF48 and Rta are shown. (B) 5' serial truncations of the RRV Rta promoter regionwere constructed in the pGL2 ﬁreﬂy luciferase backbone. (C) Luciferase activity was
measured in extracts from permissive Vero cells transfected with pGL2 R-Rta promoter deletion clones and normalized using pRL-CMV. Error bars represent the standard deviation
of results from triplicate wells. The region from 136 to 102 containing the conserved Sp1 binding site was critical for Rta promoter activity.
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Rta promoter activity (Fig. 7B), indicating that the Sp1 site at 113
was critical for high-level Rta promoter activity in permissive cells.
A similar reduction in activity was seen in the butyrate-treated
HSG cells (Fig. 7B), indicating that the Sp1 site at 113 was also
required for butyrate-responsiveness of the RRV Rta promoter
in non-permissive cells. This result mirrors previous reports for
the KSHV Rta promoter, which showed that the conserved Sp1
site was critical for butyrate induction in non-permissive cells
(Lu et al., 2003; Ye et al., 2005).
The KSHV and RRV Rta promoters have similar activities in a panel of
cell lines
Our studies demonstrated that Vero and HEK293 kidney cell
lines were permissive for RRV replication with expression of
the early lytic gene, ORF59, and production of infectious virions.
We also determined that HSG and AGS orogastric epithelial cell
lines are non-permissive for RRV replication with no expression of
the early lytic gene ORF59 or evidence of virus replication. We and
others have shown that KSHV infection of Vero and HEK293 cells
is non-permissive for viral replication with high numbers of
latently infected cells expressing nuclear LANA. At most, only
1–5% of infected cells expressed ORF59, indicating minimal levels
of viral replication. On the other hand, KSHV infection of AGS cells
resulted in high numbers of latently infected cells expressing LANA
(Supplementary Fig. 2) with no ORF59-positive cells (data not
shown). In other studies, we have shown that HSG cells are not
susceptible to KSHV infection until reconstitution of the αvβ3
integrin receptor by transfection, which results in a characteristic
latent KSHV infection (unpublished observations).
The availability of epithelial cell lines with different permissiv-
ity for KSHV and RRV replication allowed us to directly compare
how the Rta promoters of these viruses function in the context
of latency and replication. For this comparison, we cloned 503
nucleotides of KSHV Rta promoter sequence upstream of the ﬁreﬂy
luciferase reporter gene to create pGL2 K-Rta, as described in
Materials and methods. The pGL2 R-Rta and pGL2 K-Rta constructs
were transfected into AGS, HSG, Vero, and HEK293 cells and
the luciferase activity was determined in the presence or absence
of sodium butyrate treatment. pRL-CMV was co-transfected to
control for transfection efﬁciency. pGL2 luciferase activity was
normalized using the pRL luciferase activity, as described pre-
viously. Both the RRV and KSHV Rta promoters had low Rta
promoter activity (RLUo1) in untreated AGS and HSG cells
(Fig. 8). Butyrate treatment of AGS and HSG cells induced the
activities of both promoters 3.3–4.8-fold, with levels of activity
ranging from 2.7 to 3.5 RLU. Both promoters had similar levels of
Rta activity in untreated Vero and HEK293 cells (RLU¼6.7–9.1).
The KSHV and RRV Rta promoter activities were induced 2.4 and
2.7 fold by butyrate treatment of Vero cells, and 10.5 and 6.2 fold
by butyrate treatment of HEK293 cells, respectively (Fig. 8).
Surprisingly, both promoters showed similar levels of activity in
each cell line tested, suggesting that the promoters were similarly
activated by host factors in these cells.
Rta promoter activity correlates with permissivity of RRV infection
but not KSHV infection
As shown in Fig. 8, low levels (RLUo1) of RRV and KSHV Rta
promoter activity were associated with non-permissive infections
of the AGS and HGS cells with both viruses, characterized by the
complete lack of expression of the lytic replication marker ORF59
and no production of infectious virus. The high levels (RLU 1–10)
of Rta promoter activity detected in butyrate-treated AGS and HSG
cells and in untreated Vero and HEK293 cells were associated with
RRV replication, suggesting that this level of Rta promoter activity
was sufﬁcient to induce the widespread expression of the lytic
replication marker ORF59 and virus production in infected cells.
However, the same levels of Rta promoter activity were insufﬁ-
cient to induce KSHV replication in the untreated Vero and
HEK293 cells or butyrate treated AGS cells, as only minimal
numbers of infected cells (1–5%) express the ORF59 lytic replica-
tion marker. Finally, super-induced levels (RLU 10–100) of Rta
promoter activity were detected in butyrate-treated Vero and
HEK293 cells, and were associated with widespread ORF59
Fig. 7. The conserved Sp1 element is critical for RRV Rta promoter activity. (A) The
Sp1 site in the critical RRV Rta promoter region was eliminated by site-directed
mutagenesis in the full length pGL2 R-Rta construct. The conservation between
the RRV and KSHV Sp1 sites are shown and the nucleotides matching the Sp1
consensus sequence (Nagaoka et al., 2001) are highlighted. (B) Permissive Vero,
HEK293 and HSG cells were transfected with either wild type pGL2 R-Rta or the
Sp1 mutant and promoter activity was measured at 24 h. pRL-CMV was co-
transfected to control for transfection efﬁciency. The HSG cells were incubated
with sodium butyrate 5 h post transfection. Promoter activity, after normalization
with pRL-CMV, is reported as percent of maximum activity. Mutagenesis of the RRV
Sp1 site abrogated the RRV Rta promoter activity in all three permissive cell types.
Error bars represent standard deviation from triplicate wells.
Fig. 8. Comparison of KSHV and RRV Rta promoter activity. pGL2 R-Rta and pGL2 K-Rta
containing the RRV and KSHV Rta promoters directing luciferase expression, respec-
tively, were transfected into AGS, HSG, Vero and HEK293 cells and luciferase activity was
measured at 24 h. pRL-CMVwas cotransfected to control for transfection efﬁciency. Cells
were treated with sodium butyrate as indicated. Luciferase activity was measured and
normalized to pRL-CMV. Low levels of Rta promoter activity (RLUo1) were associated
with non-permissive infections with both KSHV and RRV. High levels of Rta promoter
activity (RLU 1–10) were associated with non-permissive infections with KSHV and
permissive infections with RRV leading to virus replication. Super-induced levels of Rta
promoter activity (RLU410) were required for permissive KSHV infections.
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expression and virion production in KSHV-infected cultures. Since
there is sufﬁcient Rta promoter activity in the untreated HEK293
and Vero cells and butyrate-treated AGS and HSG cells to induce the
cascade of lytic replication of RRV, the inability of KSHV to replicate in
these cells suggests that KSHV downregulates Rta promoter activity in
a process that is not shared by RRV.
RRV LANA inhibits RRV replication in permissive cells
Previous studies have shown that KSHV LANA plays a major
role in inhibiting the cascade of lytic gene expression and virus
replication induced by Rta early after infection (Lan et al., 2004;
Matsumura et al., 2005). To determine whether RRV LANA can play
a similar role in RRV infections, we transfected permissive Vero
cells with pCDNA3 N-Flag R-LANA, a construct that expresses Flag-
tagged RRV LANA from the highly active CMV IE promoter. Empty
pCDNA3 was transfected as a negative control. LANA-transfected
cell cultures were subsequently infected with RRV and evaluated
2 days post-infection for evidence of RRV replication using the
anti-RV2 ORF59 antiserum. Nuclei were visualized with TO-PRO
and expression of recombinant LANA was evaluated using an anti-
Flag antibody. Cells transfected with empty pCDNA3 vector and
infected with RRV yielded high numbers of ORF59-positive cells
(Fig. 9E; green), consistent with the permissive nature of these
cells for RRV replication with widespread viral replication. Cells
transfected with the LANA expression plasmid and infected with
RRV showed abundant expression of Flag-tagged RRV LANA
(Fig. 9D; red). Analysis of the ORF59 expression in the LANA-
transfected cell cultures revealed minimal numbers of ORF59-
positive cells (Fig. 9F; green), indicating that the LANA-transfected
cell cultures were no longer permissive to widespread RRV
replication. Analysis of the merged ORF59 (green) and LANA
(red) images (Fig. 9H) revealed that the few ORF59 positive cells
detected in the transfected culture were LANA-negative, indicating
that they had not been successfully transfected with the LANA
expression plasmid. The LANA positive cells (red) showed no
evidence of ORF59 (green) expression (Fig. 9H and insert). Sub-
sequent butyrate treatment of the LANA-transfected, RRV-infected
cultures revealed strong ORF59 expression in the LANA-positive
cells (data not shown). Thus, the LANA-expressing cells were
susceptible to RRV infection, but were not permissive for expres-
sion of the ORF59 lytic replication marker. These data suggest that
RRV LANA did not inhibit viral entry or infection, but instead
blocked the lytic replication gene cascade. Sodium butyrate was
able to overcome the LANA-mediated inhibition, allowing the
replication gene cascade to proceed.
RRV LANA is a potent inhibitor of Rta promoter activity
Previous studies have shown that RRV LANA inhibits the Rta-
induced transactivation of viral promoters responsible for the
cascade of lytic gene expression leading to virus replication
(DeWire and Damania, 2005; Wen et al., 2009). To determine
whether RRV LANA has a direct effect on the RRV Rta promoter,
we performed luciferase reporter assays in permissive Vero cells
expressing RRV LANA. The RRV Rta promoter construct pGL2-R-Rta
Fig. 9. RRV latency associated nuclear antigen (LANA) inhibits RRV replication in Vero
cells. Cells were transfected with either pcDNA3 N-Flag R-LANA or empty pcDNA3,
infected with RRV and evaluated 2 days post-infection for evidence of replication by
detection of the ORF59 lytic cycle replication marker. (A–B) To-PRO stained cells show
cell nuclei (blue). (C–D) Expression of the transfected RRV LANAwas evaluated with an
anti-Flag antibody (red). (E–F) ORF59 expression was evaluated with an anti-RV2
ORF59 antibody (green). (G) Merge of panels C and E. (H) Merge of panels D and F
showing that only LANA-negative cells expressed the ORF59 marker of RRV replication.
Fig. 10. RRV LANA inhibits RRV Rta promoter activity. Vero cells were transfected
with either the pGL2 K-Rta promoter construct and increasing amounts of pcDNA3
N-Flag K-LANA (triangles) or pGL2 R-Rta and increasing amounts of pcDNA3 N-Flag
R-LANA (squares). pRL-CMV was used to control for transfection efﬁciency.
Luciferase values were measured 24 h post-transfection, normalized to pRL-CMV,
and are shown as percent of maximal activity. The amount of total DNA in each well
was held constant with empty pcDNA3 vector. While KSHV LANA modestly
inhibited the KSHV Rta promoter, as previously shown (Lan et al., 2004), RRV
LANA highly inhibited the RRV Rta promoter, in a dose-dependent fashion.
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was transfected with increasing amounts of pCDNA3 N-Flag
R-LANA, and luciferase activity was measured at 24 h. To compare
with KSHV, we also evaluated the ability of KSHV LANA to inhibit
the KSHV Rta promoter by transfecting Vero cells with pGL2-K-Rta
and pCDNA3 N-Flag K-LANA, which expresses KSHV LANA with an
N-terminal Flag tag. We observed a dose-dependent inhibition
of KSHV Rta promoter activity by KSHV LANA, with a maximal
inhibition of 50% at the highest plasmid concentration tested
(Fig. 10). This conﬁrms previous results showing that KSHV LANA
inhibits KSHV Rta promoter activity (Lan et al., 2004). RRV LANA
strongly inhibited the RRV Rta promoter with greater than 60%
inhibition at the lowest plasmid concentration tested. A dose-
dependent response was detected with increasing inhibition to a
maximal level of 80%. These results demonstrate that the RRV
Rta promoter can be strongly downregulated by RRV LANA and
suggests that the inhibition of RRV replication by LANA that we
detected in the transfected cell cultures was mediated through
inhibition of the Rta promoter. Thus, the differential ability of
KSHV and RRV to establish latency and replicative infection in cells
that have high Rta activity, such as Vero and HEK293, may be due
to differential expression of the Rta inhibitor, LANA.
Discussion
Previous studies have identiﬁed and characterized in vitro
culture systems to study latent infections of KSHV in non-
permissive cells and replicative infections of RRV in permissive
cells. Here we describe additional cell lines that are non-
permissive for RRV replication and recapitulate the latent infection
systems and virus reactivation processes that have been charac-
terized for KSHV. This has allowed us to study the function of the
RRV Rta promoter in natural permissive and non-permissive
systems, something that has been difﬁcult for KSHV. We have
identiﬁed the human gastric epithelial (AGS) and the human
salivary epithelial (HSG) cell lines as non-permissive for RRV
infection, with no virus replication or production of infectious
virions. The AGS and HSG cells were also non-permissive for KSHV
replication, although the HSG cells lack the αvβ3 integrin receptor
and are only susceptible to KSHV infection when αvβ3 is ectopi-
cally expressed (unpublished observations). Although these cell
lines represent novel systems for studying KSHV and RRV latency,
more study is needed to understand gene expression and viral
persistence in these cells.
We have developed a polyclonal anti-RV2 ORF59 antiserum
that is reactive with the RRV ORF59 DNA polymerase processivity
factor. We have shown that rhesus ﬁbroblasts and African green
monkey Vero cells are permissive for RRV replication and produce
infectious virus. RRV-infected ﬁbroblast and Vero cells express
ORF59 transcripts early after RRV infection with concomitant
accumulation of ORF59 in the nucleus that is reactive with the
anti-ORF59 antiserum (Bruce et al., 2009). Thus, nuclear expres-
sion of RRV ORF59 is an early marker of virus replication. We did
not detect any RRV-infected HSG and AGS cells expressing the
ORF59 replication marker using the ORF59 antiserum. In contrast,
butyrate treatment of RRV-infected HSG and AGS cells induced
widespread ORF59 expression and virus replication, recapitulating
the butyrate-induced reactivation of latent KSHV infections in
pleural effusion lymphoma (PEL) cell lines, such as BCBL-1, and in
KSHV-infected HEK293, Vero and other cell lines. Interestingly,
while KSHV-infected AGS cells expressed signiﬁcant levels of the
latency antigen LANA, butyrate treatment did not induce wide-
spread ORF59 expression (unpublished observations). AGS cells
may be less efﬁciently reactivated because of low basal levels of
Rta promoter activity.
It was previously reported that the HEK293 human embryonic
kidney cell line is not fully permissive for RRV replication, based
on the lack of plaque formation, and an RRV latency system was
developed in which infected HEK293 cells were cultured long-
term in ganciclovir, an inhibitor of viral replication that speciﬁcally
targets the viral DNA polymerase (DeWire and Damania, 2005).
We found, however, that our ATCC HEK293 cells were permissive
for RRV replication and showed strong expression of the ORF59
replication marker in expanding foci of infected cells with con-
comitant production of infectious virus, similar to that seen with
RPFF cells. The different outcomes of RRV infection in HEK293 cells
may be due to differences in the strain of RRV used for infection, as
our studies used the 17577 RRV strain, while DeWire's study used
the 26–95 strain. Additionally, differences in the HEK293 cell lines
or passages could contribute to the differences in permissivity.
Our studies demonstrated that the RRV Rta promoter was
highly active in permissive cells, such as Vero and HEK293, in
which RRV replicates, and minimally active in non-permissive
cells, such as AGS and HSG, which are susceptible to infection but
are not permissive for viral replication. In non-permissive cells,
sodium butyrate treatment induced high-level RRV Rta promoter
activity and RRV replication. An Sp1 element at 113 within the
RRV Rta promoter was required for promoter activity in permissive
cells and butyrate responsiveness in non-permissive cells. This Sp1
element is highly conserved with an Sp1-binding site in KSHV that
is critical for butyrate induction of the KSHV Rta promoter in non-
permissive cells (Lu et al., 2003; Ye et al., 2005). Our ﬁnding that
high-level RRV Rta promoter activity correlates with cellular
permissivity for RRV replication suggests that host factors, such
as Sp1, regulate RRV Rta expression and the downstream induction
of the lytic gene cascade and virus replication in infected cells.
Current studies are ongoing to examine the role of Sp1 in Rta
regulation.
Our study adds to a growing number of reports linking butyrate
treatment and Sp1 activity (Kim et al., 2004; Omotehara et al.,
2002; Yang et al., 2001a; Zhang et al., 2009). How sodium butyrate
alters Sp1 binding and activity is not completely understood.
Sp1 is widely expressed, and its activity is known to be highly
regulated by multiple mechanisms, including transcriptional con-
trol, post-translational modiﬁcation, and degradation (Fojas de
Borja et al., 2001; Majumdar et al., 2003; Merchant et al., 1999;
Yang et al., 2001b). A previous report by Ye et al. showed that
butyrate augments Sp1 binding to the KSHV Rta promoter, con-
sistent with the model that butyrate enhances the functionality of
Sp1 or Sp1-containing complexes (Ye et al., 2005). While it has
been suggested that the Sp1 site in the Rta promoter plays an
important role in epigenetic silencing of Rta expression during
KSHV latency (Gunther and Grundhoff, 2010; Lu et al., 2003), the
role of epigenetic regulation in RRV latency is unknown. However,
our study suggests that the Sp1 site in the Rta promoter may play
an important role in regulating RRV replication. Interestingly, we
did not identify any sequence conservation with other transcrip-
tion factor binding sites that have been characterized in the KSHV
Rta promoter. While our studies suggest a role for Sp1 in the
reactivation and replication of RRV, other host transcription factors
may also play a role in these processes.
We found that the activities of the KSHV and RRV Rta pro-
moters were essentially identical in all cell lines tested, indicating
that the promoter structures and critical host factors regulating
promoter activity were analogous. Both promoters had minimal
activity in the HSG and AGS orogastric epithelial cells, which
correlated with non-permissive phenotypes of these cells for both
KSHV and RRV replication. Sodium butyrate treatment of the HSG
and AGS cells increased the activity of both Rta promoters to the
levels seen in untreated HEK293 and Vero cells. This level of Rta
promoter activity was sufﬁcient to induce the cascade of lytic gene
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expression leading to RRV replication in permissive HEK293 and
Vero cells and butyrate-treated HSG and AGS cells but was unable
to drive the lytic gene expression leading to KSHV replication. This
suggests that the KSHV Rta promoter was down-regulated by viral
factors present early after KSHV infection, leading to viral latency
rather than replication. This is consistent with the current under-
standing that KSHV LANA mediates shutoff of KSHV Rta expression
(Lan et al., 2004; Matsumura et al., 2005). We found that sodium
butyrate treatment of HEK293 and Vero cells increased the activity
of both KSHV and RRV Rta promoters to very high (super-induced)
levels, which correlated with reactivation of latent KSHV infection
and induction of virus replication. This suggests that the super-
induced levels of Rta promoter activity were sufﬁcient to over-
come inhibitory effects of LANA, allowing Rta induction of the lytic
gene cascade and KSHV replication.
To understand why RRV replication in HEK293 and Vero cells
was not similarly blocked by viral factors, such as LANA, we
examined the ability of RRV LANA to inhibit RRV Rta promoter
activity. It is known that KSHV LANA shuts off the viral replication
cascade through direct repression of the Rta promoter (Lan et al.,
2004; Matsumura et al., 2005). We conﬁrmed the inhibitory
effects of KSHV LANA on the KSHV Rta promoter and demon-
strated that RRV LANA can directly inhibit the RRV Rta promoter in
a dose-dependent fashion. Our ﬁndings contrast with those from a
previous study, which found no effect of RRV LANA on the RRV Rta
promoter (DeWire and Damania, 2005). This may be due to
differences in approach, as we assayed for direct LANA inhibition
of the RRV Rta promoter, while DeWire et al. normalized their
data to detect LANA inhibition of Rta transactivation of the Rta
promoter rather than direct Rta inhibition (DeWire and Damania,
2005). We also showed that ectopic expression of RRV LANA in
permissive cells, such as Vero, completely blocked expression of
the early lytic gene ORF59 in cells expressing LANA, indicating that
RRV replication was inhibited by LANA. Coupled with our ﬁnding
that RRV LANA can inhibit the RRV Rta promoter, this indicates
that the block in RRV replication by LANA was due to direct
inhibition of the Rta promoter. This was substantiated by our
ﬁnding that sodium butyrate, which activates the RRV Rta pro-
moter, could relieve the LANA-induced inhibition of replication.
The previous study by DeWire et al. detected a 50% decrease in
RRV replication in RRV-infected rhesus ﬁbroblasts ectopically
expressing LANA. However, since they detected no direct effect
of RRV LANA on the Rta promoter, they concluded that the
inhibition of replication was due to LANA interference with Rta
transactivation of lytic promoters. Our studies clearly show that
RRV LANA can block RRV replication through direct inhibition of
the RRV Rta promoter.
In cells, such as Vero and HEK293, that have high KSHV Rta
promoter activity but are non-permissive for KSHV replication, it is
believed that Rta expression is down-regulated by LANA. In KSHV,
the constitutive LANApc promoter regulates expression of a
spliced LANA transcript that originates from the adjacent K14
coding region (Fig. 11). However, immediately after KSHV infec-
tion, Rta induces LANA expression through a second Rta-inducible
LANApi promoter located within the intron region that is spliced
out of the latent LANA transcript produced from the LANApc
promoter (Lan et al., 2005; Lu et al., 2011; Matsumura et al.,
2005). High-level expression of LANA coupled with the shut-off of
Rta expression leads to the establishment of KSHV latency. The
KSHV Rta-inducible LANApi promoter contains two RBP-Jk binding
sites and an Rta-response element (RRE) adjacent to a TATA box
that are critical for the Rta-mediated induction of KSHV LANA
expression (Fig. 11) (Hilton and Dittmer, 2012). We have recently
sequenced the complete genome of RFHV, the macaque homolog
of KSHV, and have compared the RFHV and KSHV genome
sequences. We identiﬁed a conserved RBP-Jk binding site adjacent
to a conserved TATA box in the intron region of the RFHV latent
LANA transcript, suggesting that RFHV also contains an Rta-
inducible LANApi promoter (Bruce et al., in press). Though the
RRV LANA promoter region has not been fully characterized, the
lytic and latent LANA transcriptional start sites have been co-
localized to the same region within the R14 coding sequences
(DeWire and Damania, 2005), similar to the position of the
latency-associated constitutive LANApc promoter of KSHV
(Fig. 11). Analysis of the RRV LANA sequence corresponding to
the position of the Rta-inducible LANApi promoter within the
spliced intron of KSHV failed to identify a comparable TATA-like
promoter element or RBP-Jk binding sites, which are required for
LANApi promoter activity in KSHV. Furthermore, none of the
characterized RRV LANA transcripts initiate within this region.
This analysis suggests that RRV lacks a conserved homolog of the
KSHV Rta-inducible LANApi promoter and therefore lacks this
mechanism for inducing the expression of sufﬁcient levels of LANA
to mediate the establishment of latency in cells expressing Rta.
The lack of Rta-induced LANA expression could explain the ability
of RRV to replicate in cells in which KSHV infections are latent.
Previously, we have detected a very low level of RRV LANA
transcripts in permissive RRV infections of Vero cells (Bruce
et al., 2009), suggesting that low levels of RRV LANA were not
sufﬁcient to overcome the Rta promoter activity induced by host
factors like Sp1. Interestingly, elimination of a critical RBP-Jk
binding site within the KSHV LANApi promoter created a novel
recombinant KSHV that induced lytic replication during primary
infection, recreating the permissive types of infections seen with
RRV (Lu et al., 2011).
It is also possible that post-translational regulatory mechan-
isms, such as subcellular localization, could affect the ability of
RRV LANA to inhibit Rta expression. Although antibodies speciﬁc
for RRV LANA have not yet been developed, ectopic expression of
RRV LANA fused to an enhanced green ﬂuorescent protein (EGFP)
revealed that RRV LANA has a different sub-nuclear localization
than KSHV LANA and localizes to the nucleolus (DeWire and
Damania, 2005). We have conﬁrmed these ﬁndings and have
identiﬁed differences in the nuclear localization pathways utilized
by KSHV and RRV LANAs that could account for these distinct
Fig. 11. Comparison of the promoter regions of the LANA homologs of KSHV and
RRV. (A) Schematic of the bi-directional promoter region for the LANA (leftward)
and K14 (rightward) homologs in KSHV and RRV. The coding regions for the ORF73
homologs (K-LANA and R-LANA) and ORF74 homologs (K14 and R14) are indicated
as large open arrows. The homologous ORF74 “TATAA” promoter elements (K14p
and R14p) are shown. The latency-associated constitutive LANA promoter (LANApc)
of KSHV and the Rta-inducible LANA promoter (LANApi) are shown. Splice acceptor
(SAa, SAb) and splice donor (SD) sites utilized to produce the latent spliced LANA
transcripts are indicated (Dittmer et al., 1998; Sarid et al., 1999; Talbot et al., 1999).
RBP-Jkappa and RRE binding sites in LANApi are shown. RNA transcript and
sequence analysis of the RRV LANA gene revealed no evidence for an inducible
promoter analogous to the Rta-inducible KSHV LANApi promoter.
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localization patterns (unpublished results). Thus, nucleolar RRV
LANA may be unavailable to inhibit the Rta promoter in the viral
genome located in nuclear replication complexes.
Conclusions
Our studies provide an explanation for the differences observed
in the ability of RRV and KSHV to establish lytic and latent
infections in vitro. Both viruses establish non-permissive (latent)
infections in cells in which Rta promoter activity is low or absent.
The dependence of Rta promoter activity on the Sp1 site suggests
that the low Rta promoter activity in these cells is linked to low
levels of active Spl. In cells with sufﬁcient levels of active Sp1 and
Rta promoter activity to drive RRV Rta-induced lytic gene expres-
sion, RRV infections are permissive for virus replication. In the
same cells, however, KSHV infections are latent as the Rta levels
are not sufﬁcient to overcome the inhibitory effects of LANA
produced from the Rta-induced LANApi pathway. Our data suggest
that the presence of the LANApi pathway in KSHV requires a
super-induction of the KSHV Rta promoter to overcome the
inhibitory effects of LANA and drive KSHV replication in an
infected cell. Although we found that RRV LANA can directly
inhibit the RRV Rta promoter, there was no evidence of a compar-
able Rta-inducible LANApi promoter that would induce latency in
cells where the Rta promoter was active. Our study sheds light on
the differential ability of RRV and KSHV to establish latent and
replicative infections in different cell types and characterizes the
interplay of Sp1, Rta and LANA in determining the outcome of the
infection.
Materials and methods
Plasmids
The pGL2-R-Rta plasmid containing 502 nucleotides of the RRV
Rta promoter sequence was a gift from Dr. B. Damania. Truncated
fragments of the Rta promoter were prepared from pGL2-R-Rta
and inserted upstream of the ﬁreﬂy luciferase reporter gene in
pGL2 basic (Promega) using KpnI and SacI restriction sites and the
following forward primes: 487 (5' ATAAGGTACCTCGCGTGATCTTTT
3'), 443 (5' ATATGGTACCTAACAAACCTCACTCCCTGTAA 3′), 414 (5′
ATATGGTACCATAAGGTCCGTTCTTTCTATC 3′), 385 (5′ ATATGGTA-
CCTGAATCTATAGTTACATCTTTAAG 3′), 321 (5′ ATAAGGTACCTTAA-
AAAATCGCAAAAGCGAC 3′) 299 (5′ ATAAGGTACCGATGGCTCTA-
TCCGCGTT 3′), 263 (5′ ATAAGGTACCTAGTCACGATGGATCTCCAG-
T 3′), 216 (5′ AATAGGTACCTTAACTGGAATGGAAACAGC 3′) 187 (5′
ATATGGTACCGTGAACTTCCTGATGTCTCCTA 3′), 153 (5′ ATAAGG-
TACCAAACAGAGCTAAATACCAATGAC), 136 (5′ AATAGGTACCAAT-
GACTGTCACCCCTACCC 3′), 102 (5′ ATAAGGTACCGTACTATTAGACC-
AGGGGTGAG 3′), 73 (5′ ACTTGGTACCCTATCCTTTAAAAACCCA-
TACG 3′). The same reverse primer was used for all RRV Rta
promoter clones: (5′ ACTTGAGCTCTTTATGACAGGCGTC 3′). Muta-
genesis of the Sp1 site at nucleotide 113 in pGL2-R-Rta was done
by site directed mutagenesis (Mutagenex). pGL2-K-Rta, containing
the KSHV Rta promoter upstream of the luciferase reporter gene,
was constructed by amplifying the promoter sequence from KSHV-
infected BCBL-1 cells using the following primers: forward
(50 ATTAGAGCTCGCTGTTGCCTGGCATTTTGC 3′) and reverse (5′
ATTAACGCGTTTTTGTGGCTGCCTGGACAG 3′). The KSHV Rta pro-
moter sequence was inserted into pGL2 using the SacI and MluI
sites. All constructs were veriﬁed by sequencing. The pRL-CMV
plasmid, containing the CMV IE promoter driving a Renilla
reporter gene, was obtained from Promega.
pCDNA N-Flag RRV LANA, containing the RRV 17577 strain
ORF73 coding sequence with an N-terminal Flag tag, was con-
structed by inserting the RRV LANA sequence ampliﬁed from
pRRV73GFP (Burnside et al., 2006) into pCDNA3 using HindIII
and XbaI sites and the following primers: forward (5′ TAG-
CAAGCTTGCCACCATGGATTACAAGGATGACGACGATAAGTGGGG-
CAGCCGGCAA 3′, Flag coding sequence underlined) and reverse (5′
GCTATCTAGATTAGTGCTGAATTGGTAGTCCTCTG 3′). The pCDNA N-
Flag KSHV LANA expression plasmid was constructed by ligating
an insert with a Flag tag and the 14 N-terminal amino acids of
KSHV LANA (up to the AscI site in the LANA coding sequence) and
an insert containing the remaining 989 C-terminal amino acids
(downstream of the AscI site) into the pCDNA3 vector. Brieﬂy,
overlapping oligos encoding an initiating methionine, Flag sequence
and the ﬁrst 14 amino acids of KSHV LANAwere denatured at 95 1C for
4 min in 100mM potassium acetate, 2 mM magnesium acetate, and
20mM HEPES and then annealed at 70 1C for 10 min. The oligos were
designed such that the annealed oligo insert had KpnI and AscI
overhangs. The KSHV LANA coding sequence (minus the 14 N terminal
amino acids) was excised from pCDNA3.1 V5/HISA orf73 (Renne et al.,
2001) with AscI and XhoI. Both inserts were subcloned into pUC19
using KpnI and Xho sites. The resulting pUC19/NFlag KSHV LANA
plasmid was conﬁrmed by diagnostic digest. The entire N-Flag KSHV
LANA sequence was then excised and cloned into pCDNA3 using
KpnI and XhoI sites. LANA expression constructs were veriﬁed by
sequencing.
Cell and virus stocks
Human salivary gland (HSG) epithelial cells (Shirasuna et al.,
1981) were a kind gift of Dr. K. Izutsu. Gastric adenocarcinoma
(AGS) epithelial cells (Pinto-Santini and Salama, 2009) were
provided by Dr. N. Salama. Rhesus primary fetal ﬁbroblast (RPFF)
cells and RRV strain 17577 were kindly provided by Drs. M.
Axthelm and S. Wong. HEK293 human embryonic kidney cells
and African green monkey kidney epithelial (Vero) cells were
obtained from the ATCC. All cells were maintained in Dulbecco's
modiﬁed Eagle's medium supplemented with 10% cosmic calf
serum, 1% penicillin–streptomycin and 1% HEPES. RRV virions
were harvested by ultracentrifugation of supernatants from
infected RPFF cell cultures as previously described (Bruce et al.,
2009). KSHV virions were gradient puriﬁed from ﬁltered culture
supernatants of TPA-treated BCBL-1 cells, as described (Garrigues
et al., 2008).
Immunological reagents
The KSHV LANA rat monoclonal antibody (clone LN53) and
ORF59 mouse monoclonal antibody were obtained from Advanced
Biotechnologies Inc (ABI). The 425 rabbit polyclonal anti-RV2
ORF59 antisera was prepared by immunizing a rabbit with the
coding sequences for amino acids 300–388 of ORF59 of the RRV
(17577) and MneRV2 (442 N), as described previously (Bruce et al.,
2009). M2 anti-Flag antibody (Sigma), Alexa488-conjugated goat
anti-rabbit secondary antibody and Alexa594-conjugated goat
anti-mouse secondary antibody (Molecular Probes), horse-radish
peroxidase (HRP)-coupled goat anti-rat IgG (Biosource) and
normal goat serum (Jackson) were purchased.
Immunoﬂuorescence assays
To detect the lytic gene cascade characteristic of a permissive
RRV infection, we developed an immunoﬂuorescence assay to
detect the nuclear accumulation of the early lytic gene ORF59, the
DNA polymerase processivity factor, using the 425 rabbit anti-RV2
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ORF59 antiserum, which is reactive with RRV ORF59, as described
previously (Bruce et al., 2009). ORF59 expression was visualized
using an Alexa488-conjugated goat anti-rabbit secondary antibody
(Molecular Probes). Flag-tagged RRV LANA expression was visua-
lized using the M2 anti-Flag antibody (Sigma) and Alexa594-
conjugated goat anti-mouse secondary antibody. KSHV LANA was
visualized using the LN53 rat anti-LANA antibody and goat anti-rat
IgG-coupled to HRP, as described (Garrigues et al., 2008). KSHV
ORF59 was visualized using the monoclonal antibody reactive
with KSHV ORF59. Cell nuclei were stained with TO-PRO. Images
were acquired with a Zeiss LSM 5 Pa confocal microscope.
Virus infection
For RRV infections, cells were plated onto 17 mm spots, cultured
overnight, and incubated with RRV for 3 h at 37 1C. To determine if
the RRV infections were permissive, a low MOI (0.005) was used to
allow local transmission of infection to adjacent cells. The infected
cells were washed, cultured for 3 days and then evaluated for the
presence of spreading ORF59-positive foci, using the 425 rabbit anti-
RV2 ORF59 antiserum, as described previously (Bruce et al., 2009). To
determine whether the infection was productive for infectious virus,
the cell supernatants were removed and incubated with permissive
RPFF or Vero cells. The cells were evaluated after 2 days for the
presence of ORF59-positive RRV-infected foci.
To determine if the RRV infections were latent, infected cultures
that were ORF59-negative were treated 3 h post-infection with 4 mM
sodium butyrate (Millipore) to induce virus replication, and the
cultures were evaluated 3 days later for the presence of ORF59-
positive foci and infectious virus, as described above.
For comparison purposes, BCBL-1 cells, latently-infected with
KSHV, were incubated with a monoclonal antibody reactive with
KSHV ORF59 (Advance Biotechnologies) before and after treat-
ment with 4 mM sodium butyrate for 24 h to determine the
replicative state of the virus. For KSHV infections, AGS cells were
incubated with gradient-puriﬁed KSHV, cultured for 24 h and ﬁxed
in paraformaldehyde. KSHV LANA was visualized using the LN53
rat anti-LANA antibody and goat-anti-rat IgG-coupled to HRP, as
described (Garrigues et al., 2008).
For LANA inhibition studies, cells were transfected with 200 ng
pCDNA3-N-Flag RRV LANA and incubated with puriﬁed RRV
virions 8 h post-transfection. Flag-tagged RRV LANAwas visualized
using the M2 anti-Flag antibody (Sigma) and Alexa594-conjugated
goat anti-mouse secondary antibody. Cell nuclei were stained with
TO-PRO. Images were acquired with a Zeiss LSM 5 Pa confocal
microscope.
Reporter assays
Cells were cultured on 6-well plates and transfected with 3 mg
of ﬁreﬂy reporter gene construct (either empty pGL2, pGL2-R-Rta
or pGL2-K-Rta) and 5 ng of Renilla luciferase pRL-CMV as an
internal control for transfection efﬁciency using LT1 reagent
(Mirus). For butyrate-treated wells, butyrate was added at 5 h
post-transfection to a ﬁnal concentration of 4 mM. Lysates were
harvested 24 h post-transfection using the Dual Luciferase kit
(Promega). The mean luciferase activity from triplicate wells was
determined and reported normalized to pRL-CMV activity as
relative luciferase units (RLUs). In LANA inhibition studies, repor-
ter plasmids and LANA expression plasmids were cotransfected
using LT1 reagent (Mirus). The total volume of DNA was held
constant using empty pCDNA3 vector and luciferase activity was
measured at 24 h.
Data analysis
The GraphPad Prism software was used for statistical analysis.
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